Iovanace Biotherapeutics (IOVA) PT Maintained at $30 at Chardan Capital Markets; 'Market Misunderstandings' Offer 'Buying Opportunity Ahead of Data'
Tweet Send to a Friend
Chardan Capital Markets maintained its price target on Iovanace Biotherapeutics (NASDAQ: IOVA) at $30.00 while maintaining a Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE